Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 11183
Date Received: 16/02/2026
Summary:
1. For the calendar year of 2025, please could you tell me how many individual MRI examinations were performed overall? 2. For the calendar year of 2025, please could you give a breakdown of the individual MRI examinations performed into body part/area? For instance, how many brain scans, spine scans etc. I am happy with whichever body part description is input in the PACS system. 3. As of the start of 2026, what would the waiting time be (in weeks) for a routine MRI scan (for example how long would a patient have to wait if they were referred for a routine MRI scan of their knee)? 4. How much money was paid to private companies during the calendar year 2025 for the outsourcing of MRI either to mobile MRI units, private hospitals or private companies staffing hospital scanners to scan NHS patients? 5. From question 4 which companies were used and how many patients were scanned?
Date of Response: 16/03/2026
View Response: 11183.pdf
Freedom of Information Request Reference: 11182
Date Received: 16/02/2026
Summary:
Please provide all information for the most recent full financial year for which you hold complete data, unless otherwise stated. Spend, Suppliers & Contracting 1. Total spend on: o Interpreting o Translation o Transcription 2. Who is your current supplier(s) for language services? If multiple suppliers are used, please specify which services each supplier delivers. 3. Who is your provider for non spoken language services (e.g., BSL/ISL)? 4. Who is your provider for transcription services (if separate)? 5. Do you employ any in house interpreters or translators? 6. Contract expiry dates: o a) Without extensions o b) With all extensions applied 7. Name, phone number and email address of the contract manager for language services. 8. Name, phone number and email address of the person responsible for the language services budget. 9. Do you have any minimum durations set for interpreting bookings? If yes, please specify for each service type (spoken, non spoken, telephone, video). Activity Data – Latest Full Financial Year 10. Total number of: • Face to face interpreting assignments (spoken) + total hours • Face to face interpreting assignments (non spoken) + total hours • Telephone interpreting calls + total minutes • Video interpreting calls (spoken) + total minutes • Video interpreting calls (non spoken) + total minutes • Document translations + total words translated • Audio transcriptions + total audio duration 11. Top 20 highest volume languages for interpreting/translation. Performance, Fulfilment & Complaints 12. Fulfilment rate (%) for: • Face to face interpreting • Telephone interpreting • Video interpreting • Document translation • Audio transcription 13. Number of language service complaints received in the latest full financial year. 14. Percentage of positive vs negative feedback received regarding language services. 15. Languages your provider has been unable to source in the last 12 months. 16. Have any service credits been applied in the last 12 months? If yes, what performance issues were they linked to? Social Value, Tender Information & Pricing 17. Social value delivered under this contract in the last 12 months. 18. If tendered, please provide a copy of the winning bidder’s tender submission. 19. Contracted rates for: • Spoken face to face interpreting (hourly) • Non spoken face to face interpreting (hourly) • Telephone interpreting (per minute) • Spoken video interpreting (per minute) • Non spoken video interpreting (per minute) • Document translation (per word) • Audio transcription (per audio minute) 20. Has your provider increased their rates in the last 12 months? 21. What is the Authority’s typical route to market for procuring language services? Assistive Technology (BSL / Deaf Access) 22. Do you have a VRS (Video Relay Service) on demand service in place allowing Deaf BSL users to contact you via video when phoning? 23. Do you have a VRI (Video Remote Interpreting) on demand service in place for emergency/unplanned/immediate communication needs for Deaf patients or service users? If yes to either: • Who is the provider? • When was the service introduced? • Is it available 24/7? • Is there a cost to the Authority? Additional Data for the Most Recent Full Financial Year 24. Total number of spoken language requests. 25. Total number of non spoken language requests. 26. Total spend on spoken vs non spoken language services. 27. Fulfilment rates for spoken vs non spoken services. Final Clarification Request 28. If your provider offers additional provisions or specialist services (e.g., ISL, rare languages, emergency response, in person support, or other enhanced services), please provide details.
Date of Response: 18/03/2026
View Response: 11182.pdf
Freedom of Information Request Reference: 11180
Date Received: 13/02/2026
Summary:
1. Policy and pathways 1a. Does your Trust have a written policy, guideline, or clinical pathway addressing menopause symptoms in patients treated for breast cancer? o Yes / No o If yes, please provide the document or a web link. 1b. Is menopause care for breast cancer patients addressed within:     a) Breast cancer service guidelines     b) Oncology service guidelines     c) Menopause service guidelines     d) Not formally addressed ________________________________________ 2. Service provision 2a. Does your Trust provide specialist menopause support specifically for patients with a history of breast cancer? o Yes / No 2b. If yes, which of the following are available? (Please tick all that apply) o Dedicated menopause clinic o Joint oncology–gynaecology clinic o Breast cancer nurse–led service o Referral to general menopause clinic o External referral only ________________________________________ 3. Staffing and expertise 3a. Are any of the following routinely involved in menopause management for breast cancer patients? o Breast care nurses o Oncologists o Gynaecologists o GPs with special interest in menopause o Menopause specialist nurses o Sexual health specialist (including clinician/oncologist trained in sexual health and wellbeing) o Other, please specify......................... 3b. Does your Trust provide specific training or education on menopause management in breast cancer patients for clinical staff? o Yes / No ________________________________________ 4. Patient information and support Does your Trust provide written or digital patient information, other than publicly available information, specifically addressing menopause symptoms after breast cancer treatment? o Yes / No o If yes, please provide copies or links. ________________________________________ 5. Data collection and audit 5a. Does your Trust routinely collect or audit data on menopause symptoms or menopause-related quality of life in breast cancer patients? o Yes / No 5b. Has your Trust conducted any audit, service evaluation, or quality improvement project related to menopause care in breast cancer patients in the last 3 years? o Yes / No o If yes, please provide the title and date.
Date of Response: 13/03/2026
View Response: 11180.pdf
Freedom of Information Request Reference: 11179
Date Received: 17/02/2026
Summary:
Please provide the following information: 1. Any data held by your organisation regarding NHS-employed prescribing clinicians (including but not limited to medical practitioners, dentists, nurse independent prescribers, pharmacist prescribers and allied health professional prescribers) who have left NHS Scotland employment within the last five financial years. 2. Any recorded destination-of-leaver data indicating movement into: a. Private healthcare practice b. Independent clinical practice c. Cosmetic or aesthetic medicine services d. Non-surgical cosmetic treatment providers e. Self-employment in healthcare provision 3. Any internal workforce impact assessments, modelling, workforce planning assumptions, risk registers or reports produced since 2018 that reference: a. Workforce loss to the private healthcare sector b. Workforce loss to the cosmetic or aesthetic medicine sector c. Reduced NHS clinical capacity linked to private sector migration d. Prescribers reducing NHS contracted hours in order to undertake private aesthetic practice 4. Any estimates held regarding: a. Full-time equivalent (FTE) clinical capacity lost due to prescribers undertaking private practice b. Waiting list impact associated with workforce attrition to private practice c. Training investment loss associated with prescribers leaving NHS Scotland employment 5. Any correspondence, briefing papers, or policy discussions held since 2018 relating to: a. The migration of NHS clinicians into the cosmetic/aesthetic medicine sector b. The impact of dual practice (NHS and private aesthetics work) c. Retention risks linked to private sector injectable or cosmetic treatment markets 6. Any plans, current or proposed, to: a. Monitor workforce migration into cosmetic or aesthetic medicine b. Record private sector destination data more accurately c. Mitigate workforce displacement related to private aesthetic practice
Date of Response: 18/03/2026
View Response: 11179.pdf
Freedom of Information Request Reference: 11178
Date Received: 17/02/2026
Summary:
No. Question Response Format 1 Does your Trust/Health Board currently provide or commission a Prosthetic service? 2 Does your Trust/Health Board currently provide or commission an Orthotic service for patients? 3a If you answered Yes to Question 1: Is your Prosthetic service delivered in-house (i.e. directly employed NHS staff) or is it contracted out to an external provider? 3b If you answered Yes to Question 2: Is your Orthotic service delivered in-house (i.e. directly employed NHS staff) or is it contracted out to an external provider? 4 Does your Trust/Health Board carry out workforce planning analysis for your Allied Health Professional (AHP) workforce? 5a If you answered Yes to Question 4: Does your AHP workforce planning specifically include your Prosthetic service workforce (whether in-house or contracted)? 5b If you answered Yes to Question 4: Does your AHP workforce planning specifically include your Orthotic service workforce (whether in-house or contracted)? 6a If your Prosthetic service is contracted out (as indicated in Question 3a): Does your Trust/Health Board carry out workforce planning for the contracted Prosthetic service? 6b If your Orthotic service is contracted out (as indicated in Question 3b): Does your Trust/Health Board carry out workforce planning for the contracted Orthotic service? 7a If you answered Yes to Question 6a: How does your Trust/Health Board collate workforce planning data from the contracted Prosthetic service provider? Please describe the process, including the frequency of data collection and what data is gathered. 7b If you answered Yes to Question 6b: How does your Trust/Health Board collate workforce planning data from the contracted Orthotic service provider? Please describe the process, including the frequency of data collection and what data is gathered. 8 If your Trust/Health Board does not carry out workforce planning for its Prosthetic and/or Orthotic services (whether in-house or contracted), please explain what steps you are taking to secure the prosthetic and/orthotic workforce pipeline. 9 Does your Trust/Health Board include data from its Prosthetic and/or Orthotic services (whether in-house or contracted) in any workforce returns submitted to NHS England, NHS Wales, NHS Scotland, or equivalent national workforce planning bodies? 10 Please provide the current whole time equivalent (WTE) staffing establishment for your Prosthetic and/or Orthotic services, broken down by: (a) Prosthetists, (b) Orthotists, (c) Prosthetic/Orthotic Technicians, (d) Prosthetic/Orthotic support workers (e) Please indicate whether each figure relates to in-house or contracted staff.
Date of Response: 17/03/2026
View Response: 11178.pdf
Freedom of Information Request Reference: 11177
Date Received: 17/02/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Name of medicine 1.1 Abiraterone (Zytiga or generic abiraterone) 1.2 Apalutamide (Erleada) 1.3 Cabazitaxel (Jevtana or generic cabazitaxel) 1.4 Darolutamide (Nubeqa) 1.5 Enzalutamide (Xtandi) 1.6 Talazoparib (Talzenna) 1.7 Docetaxel 1.8 Relugolix (Orgovyx, Ryeqo) 1.9 Olaparib (Lynparza) Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Name of medicine 2.1 Docetaxel for prostate cancer 2.2 Olaparib (Lynparza) for prostate cancer 2.3 Talazoparib (Talzenna) for prostate cancer 2.4 Relugolix (Orgovyx) for prostate cancer Q3. How many patients received their first cycle or first dose of the following products in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Name of medicine 3.1 Abiraterone (Zytiga or generic abiraterone) 3.2 Apalutamide (Erleada) 3.3 Cabazitaxel (Jevtana or generic cabazitaxel) 3.4 Darolutamide (Nubeqa) 3.5 Enzalutamide (Xtandi) Q4. How many patients were treated with the following combinations in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle. Name of medicine 4.1 Darolutamide (Nubeqa) + Docetaxel 4.2 Darolutamide (Nubeqa) monotherapy 4.3 Olaparib (Lynparza) + Abiraterone Q5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Name of medicine 5.1 Abiraterone 5.2 Enzalutamide
Date of Response: 17/03/2026
View Response: 11177.pdf
Freedom of Information Request Reference: 11176
Date Received: 17/02/2026
Summary:
Please provide the monthly number of patients initiated onto the medication Camzyos (mavacamten) within your Trust from January 2025 to the most recent month for which data is available.
Date of Response: 17/03/2026
View Response: 11176.pdf
Freedom of Information Request Reference: 11174
Date Received: 17/02/2026
Summary:
1. Total Spending Please provide the Trust’s annual expenditure for each of the financial years from April 2018 (FY 2018/19) to the most recent financial year available for the following categories, where the expenditure relates in full or in part to dermatology services: A. Total spend (£) on Waiting List Initiatives (WLIs) B. Total spend (£) on insourcing C. Total spend (£) on outsourcing Where dermatology expenditure is not held separately, please provide figures for any broader specialty, service line, cost centre, programme, or contract that includes dermatology activity (for example, but not limited to, medical specialties, elective recovery programmes, clinical outsourcing, or independent sector provision), and indicate how dermatology is included within that category. For the avoidance of doubt, this request includes expenditure on dermatology services delivered by independent sector, private, third-party, or digital providers, whether delivered in person or remotely regardless of how such expenditure is categorised internally. 2. Contract information As of 30th January 2026, please confirm: a. Whether the Trust has any active (live) insourcing contracts in place relating to dermatology services. If yes, for each contract please specify: o Name of the insourcing supplier o Contract end date o Total spend on supplier for financial year 2025/26 o Total spend on supplier for financial year 2024/25 b. Whether the Trust has any active (live) outsourcing contracts in place relating to dermatology services. If yes, for each contract please specify: o Name of the outsourcing supplier o Contract end date o Total spend on supplier for financial year 2025/26 o Total spend on supplier for financial year 2024/25 c. Whether the Trust has any active (live) contracts for teledermatology services in place (including advice and guidance or digital dermatology services). If yes, please provide: o Name of the provider o Contract end date o Total spend on supplier for financial year 2025/26 o Total spend on supplier for financial year 2024/25
Date of Response: 18/03/2026
View Response: 11174.pdf
Freedom of Information Request Reference: 11173
Date Received: 16/02/2026
Summary:
I wish to make a Freedom of Information Request for NHS Lothian definition of a woman.
Date of Response: 16/03/2026
View Response: 11173.pdf
Freedom of Information Request Reference: 11172
Date Received: 16/02/2026
Summary:
Please can you provide the spend for temporary staffing split for bank and agency as below covering November 2025, December 2025 & January 2026. Registered Nursing Unregistered Nursing (i.e. Health Care Assistants Medical
Date of Response: 16/03/2026
View Response: 11172.pdf
Freedom of Information Request Reference: 11171
Date Received: 16/02/2026
Summary:
I am requesting some details of NHS Lothian’s newly established GP walk in service. 1) How long is the pilot running for? 2) How many clinicians are available at any given time and what skill mix? 3) How is the service being managed - clinical staff v non clinical staff? 4) Are these staff working under AFC terms and conditions, and if so, what banding are these roles. 5) Is there any intention to include other services into this pilot, for example NHS dental services? 6) I understand that this service is for specific practices within South West Edinburgh, is there a reason for this and what is the likelihood of this extending to cover all of NHS Lothian?
Date of Response: 16/03/2026
View Response: 11171.pdf
Freedom of Information Request Reference: 11168
Date Received: 13/02/2026
Summary:
Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage): • Avelumab + Axitinib • Axitinib • Cabozantinib • Everolimus • Lenvatinib + Everolimus • Lenvatinib + Pembrolizumab • Nivolumab monotherapy • Nivolumab + Cabozantinib • Nivolumab + Ipilimumab • Pazopanib • Pembrolizumab monotherapy • Pembrolizumab + Axitinib • Radiotherapy only • Sunitinib • Temsirolimus • Tivozanib • Other active systemic anti-cancer therapy • Palliative care only Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments: • Avelumab + Axitinib (Bavencio + Inlyta) • Cabozantinib (Cometriq) • Nivolumab (Opdivo) • Nivolumab + Cabozantinib (Opdivo + Cometriq) • Nivolumab + Ipilimumab (Opdivo + Yervoy) • Lenvatinib + Pembrolizumab (Kisplyx + Keytruda) Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma? • Nivolumab (monotherapy) • Nivolumab + Ipilimumab • Nivolumab + Cabozantinib • Avelumab + Axitinib • Lenvatinib + Pembrolizumab (Kisplyx + Keytruda) • Cabozantinib (Cometriq) *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen. Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)? Q5. Does your trust participate in any clinical trials for the treatment of renal cell carcinoma? If so please provide the name of each trial and number of patients that are taking part?
Date of Response: 13/03/2026
View Response: 11168.pdf
Freedom of Information Request Reference: 11167
Date Received: 13/02/2026
Summary:
Please provide the following information, using the most recent data available, as well as the same information for the equivalent, or nearest, date in 2021 and 2016. 1. ‎ The total number (head count) of all registered nurses employed by the trust or health board at Agenda for Change Band 5 and above. 2. Of these registered nurses (Band 5 and above), how many are/were absent from work on long-term sick leave, which is defined as sickness absence lasting more than 28 consecutive calendar days.
Date of Response: 13/03/2026
View Response: 11167.pdf
Freedom of Information Request Reference: 11166
Date Received: 13/02/2026
Summary:
Please can you provide the following information for the public dental service(s) provided by your organisation for 6th April 2024 to 5th April 2025 unless otherwise stated. 1. Did your organisation provide a public dental service? Yes, we did provide a public dental service. Please continue to Question 2. No, we did not provide a public dental service. Please provide the name of the organisation that provides this service in your geographical area. You do not need to respond to the remainder of the questions in this FOIA request. 2. For each band please enter the relevant number corresponding to the column and row labels. Vocational Dental Practitioner Dental Officer Senior Dental Officer Specialist Dental Officer Assistant Clinical Director Clinical Director or CADO Other dentist:
Date of Response: 13/03/2026
View Response: 11166.pdf
Freedom of Information Request Reference: 11164
Date Received: 12/02/2026
Summary:
Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period available? Name of medicine 1.1 Abemaciclib (Verzenios) 1.2 Alpelisib (Piqray) 1.3 Elacestrant (Orserdu) 1.4 Fulvestrant (fulvestrant or Faslodex) 1.5 Inavolisib (Inaqovi) 1.6 Palbociclib (Ibrance) 1.7 Ribociclib (Kisqali) 1.8 Capivasertib (Truqap) 1.9 Talazoparib (Talzenna) 1.10 Olaparib (Lynparza) Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period for which data are available? Name of combination or monotherapy 2.1 Abemaciclib (Verzenios) 2.2 Ribociclib (Kisqali) 2.3 Olaparib (Lynparza) Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period for which data are available? Name of combination or monotherapy 3.1 Abemaciclib (Verzenios) 3.2 Ribociclib (Kisqali) Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2025 and the end of December 2025, or latest 3-month period available? Name of combination or monotherapy 4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex) 4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex) 4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex) Q5. How many patients were treated specifically for breast cancer in the 3 months between the start of October 2025 and the end of December 2025? Type of breast cancer 5.1 Olaparib - All types of breast cancer 5.2 Olaparib - Locally advanced or metastatic breast cancer 5.3 Talazoparib – All types of breast cancer Q6. How many patients were treated in total with the following products in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Name of medicine 6.1 Pertuzumab (Perjeta) 6.2 Pertuzumab with Trastuzumab (Phesgo) 6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 6.4 Trastuzumab Deruxtecan (EnHertu) 6.5 Trastuzumab Emtansine (Kadcyla) 6.6 Tucatinib (Tukysa) 6.7 Neratinib (Nerlynx) Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st October 2025 to the end of December 2025, or latest 3-months for which data are available? Name of medicine 7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 7.2 Trastuzumab Deruxtecan (EnHertu) Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available? Products 8.1 Pertuzumab (Perjeta) 8.2 Pertuzumab with Trastuzumab (Phesgo) 8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab) 8.4 Trastuzumab Emtansine (Kadcyla) Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available? Products 9.1 Pertuzumab (Perjeta) 9.2 Pertuzumab with Trastuzumab (Phesgo) 9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab) 9.4 Trastuzumab Emtansine (Kadcyla) Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of October 2025 to the end of December 2025, or latest 3-month period for which data are available? Treatment intent 10.1 HER2+ve Breast Cancer 10.2 HER2-low Breast Cancer
Date of Response: 12/03/2026
View Response: 11164.pdf
Freedom of Information Request Reference: 11163
Date Received: 12/02/2026
Summary:
Please may you provide me with the following: 1. Please state how many deceased were collected by Pure Cremations in the 2025 calendar year from your mortuary site(s)? 2. A) Does your hospital trust mortuary service have any rules on how quickly bodies must be collected by funeral directors? B) If so, please state on how many occasions in the 2025 calendar year Pure Cremations exceeded this. 3. What were the ten longest delays in these collections in the calendar year 2025? (in days) 4. Have you made any written complaints from your head of mortuary services to Pure Cremations? If so, can you provide a copy of these complaints?
Date of Response: 12/03/2026
View Response: 11163.pdf
Freedom of Information Request Reference: 11162
Date Received: 12/02/2026
Summary:
Please reveal the following information: 1. Confirmation of whether or not you record when a dental practice that provides NHS dentistry no longer provides NHS dentistry. 2. Confirm whether or not you record the reason as to why practices stop providing NHS dentistry (closing, retirement of dentist, dentist deciding to just offer private dental services etc). 3. A breakdown in the last six years of how many dental practices in Scotland stopped providing NHS dentistry (2021, 2022, 2023, 2024, 2025 and 2026 so far)
Date of Response: 13/03/2026
View Response: 11162.pdf
Freedom of Information Request Reference: 11161
Date Received: 12/02/2026
Summary:
We have reviewed your disclosure log and the specific information that we require has not been published previously. Our preference is to receive responses to requests below in an email or as an attached Word Document. a) Does your Trust currently use an Electronic Patient Record (EPR) system for inpatient clinical care? b) Please provide the name(s) of the EPR system(s) currently in use at your Trust for each of the following clinical activities (as applicable) • Medicines prescribing/administration • Medical documentation/clinical notes • Laboratory results/reporting • Vital signs/observations • Consent forms viewing/signing • Outpatient letters viewing/writing c) For each EPR mentioned above (b), please provide information on whether the EPR is used Trust-wide or only in selected clinical services. If selected clinical services, please provide details of the services for which each is applicable. d) For each EPR mentioned above (b), in which year was it first implemented for use? e) Does your Trust use paper/physical records for any of the following? • Medicines prescribing/administration • Medical documentation/clinical notes • Laboratory results/reporting • Vital signs/observations • Consent forms viewing/signing • Outpatient letters viewing/writing f) Does your Trust currently extract data from the EPR (s) for research, audit, or quality improvement purposes? If so, please provide brief details g) Is there a dedicated informatics, analytics, or digital team that supports the use of EPR data for research, audit, or quality improvement purposes?
Date of Response: 11/03/2026
View Response: 11161.pdf
Freedom of Information Request Reference: 11159
Date Received: 12/02/2026
Summary:
1. The average waiting times for category 5 CT scans between April 2021 to September 2021 for inpatients at Western General Hospital, Crewe Road South, Edinburgh and Royal Infirmary of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, Edinburgh 2. The average waiting times for CT scans undertaken where there is a suspected bowel perforation for inpatients at Western General Hospital, Crewe Road South, Edinburgh and Royal Infirmary of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, Edinburgh
Date of Response: 12/03/2026
View Response: 11159.pdf
Freedom of Information Request Reference: 11158
Date Received: 11/02/2026
Summary:
A. How many patients have been treated with the following drugs in the past 4 months: • Atogepant (Aquipta) – any disease • Erenumab (Aimovig) - any disease • Eptinezumab (Vyepti) – any disease • Fremanezumab (Ajovy) - any disease • Galcanezumab (Emgality) - any disease • Rimegepant (Vydura) – any disease • Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY B. How many patients have you treated in the last 4 months for acute migraine with: • Rimegepant (Vydura) C. Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?
Date of Response: 11/03/2026
View Response: 11158.pdf
Freedom of Information Request Reference: 11157
Date Received: 12/02/2026
Summary:
The number of immunoglobulin vials/volume in grams distributed to NHS Lothian in each month for October, November, and December 2025, broken down by product (see below). I would also like to request the number of patients by brand if available *Vigam *Flebogamma DIF *Gammaplex *Gamunex-C *Octagam *Gamten *Kiovig *Intratect *Privigen *Iqymune *Gammanorm *Subcuvia *Subgam *Hizentra *Hyqvia *Cuvitru *Panzyga *Xembify *Cutaquig • Vyvgart (Efgartigimod)
Date of Response: 12/03/2026
View Response: 11157.pdf
Freedom of Information Request Reference: 11156
Date Received: 12/02/2026
Summary:
Please see specific questions below and if the information could please be presented in Excel format it would be appreciated. •Manufacturer and model of all endoscopic imaging systems and video endoscopes in use within the trust. •Location within trust (hospital site) •Age of each unit in situ (date of manufacture or date of installation) •Associated planned replacement programmes or supplier contracts in place
Date of Response: 12/03/2026
View Response: 11156.pdf
Freedom of Information Request Reference: 11154
Date Received: 10/02/2026
Summary:
I understand that NHS Lothian does not record occupation or industry detail in an extractable way. To refine this to information that may be available from centrally-held inpatient episode or discharge coding, without reviewing individual records, could you please provide the following for calendar years 2015 to 2025 inclusive, if held. 1. Asthma admissions totals Annual totals for inpatient episodes or discharges where asthma is recorded as a primary or secondary diagnosis (for example ICD-10 J45 and any sub-codes used). 2. Any coded “work-related condition” indicator Please confirm whether your inpatient coded dataset includes ICD-10 external cause code Y96 “work-related condition”, or any local equivalent. If yes, please list the relevant code(s). 3. Use of any work-related indicator If any such indicator exists, please provide annual totals for: a) episodes where the work-related code is recorded (all diagnoses) b) episodes where asthma appears in conjunction with the work-related code.
Date of Response: 11/03/2026
View Response: 11154.pdf
Freedom of Information Request Reference: 11153
Date Received: 10/02/2026
Summary:
Wish to enquire about the number of staff (in WTE) who support acquired brain injured (ABI) patients across NHS Lothian. In particular I wish to understand the total numbers in the following disciplines: • Consultants • Non-consultant career grade doctors • AHP consultants • Physiotherapy (all grades) • Occupational therapy (all grades) • Speech and language therapists • Neuropsychologists • Nursing • Healthcare support workers (HCSW) • Dietetics • Rehab support workers • Team leaders • Admin support
Date of Response: 10/03/2026
View Response: 11153.pdf
Freedom of Information Request Reference: 11152
Date Received: 10/02/2026
Summary:
Q1. How many patients have been diagnosed with Prostate Cancer (ICD-10 code = C61) in the past 12 months? Q2. How many patients have been diagnosed with Localised Prostate Cancer (meaning the cancer is contained within the prostate and has not spread elsewhere, T1 or T2 on the TNM staging scale) in the past 12 months? Q2b. How many patients with Prostate Cancer (C61) do you have in the following risk categories based on the Cambridge Prognostic Group (CPG) Low risk prostate cancer - CPG 1 • Grade Group 1 (Gleason score of 6) • and a PSA level less than 10 ng/ml • and a T stage of 1 or 2 Medium risk prostate cancer CPG 2 and CPG 3 • Grade Group 2 or 3 (Gleason score of 7) • or a PSA level between 10 and 20 ng/ml • and a T stage of 1 or 2 High risk prostate cancer - CPG 4 and CPG 5. • Grade Group 4 (previously called a Gleason score of 8 - 10) • PSA level higher than 20 ng/ml • T stage of 3 or 4 Q3. How many patients with Localised Prostate Cancer are currently under Active Surveillance as recommended in NHS England Guidelines for the Management of Prostate Cancer? Q4. How many Prostatectomy procedures have been carried out in your Trust or organisation in the past 12- months? Q4b. How many Prostatectomy procedures have been carried out on patient with High-risk prostate cancer - CPG 4 and CPG 5 in your Trust or organisation in the past 12-months? Q5. How many patients with Prostate Cancer (ICD-10 code = C61) are currently being treated with the following hormone therapies? Q6. How many patients with Localised Prostate Cancer are currently being treated with the following hormone therapies? Q7. How many External Beam Radiotherapy (EBRT) procedures have been carried out on patients with Prostate Cancer (C61) in the past 12-months? Q8. How many Brachytherapy procedures have been carried out on patients with Prostate Cancer in the past 12-months?
Date of Response: 10/03/2026
View Response: 11152.pdf
Freedom of Information Request Reference: 11151
Date Received: 10/02/2026
Summary:
• Spend on Insourcing from November 2025-end of January 2026, broken down by each specialty and subspecialty, and the insourcing company that was used, e.g. cardiology £1000- echo cardiogram £1000- company x £1000 • The budget for each specialty for insourcing • Confirm the contract start and end date for each specialty • What frameworks were used for each specialty and was there direct awards and if so, who was they awarded to and what specialty • What was the service, e.g. theatres, outpatient, or diagnostic
Date of Response: 10/03/2026
View Response: 11151.pdf
Freedom of Information Request Reference: 11150
Date Received: 10/02/2026
Summary:
Request relation to medical record.
Date of Response: 10/02/2026
View Response: 11150.pdf
Freedom of Information Request Reference: 11149
Date Received: 09/02/2026
Summary:
I am seeking hospital-level activity data within your health authority, as outlined below. Dataset 1: ICD-10 Diagnosis Data For each hospital, please provide: • From 2022 up to the latest data available, preferably by calendar year • Primary (first) diagnosis ICD-10 codes (three or more characters), chapters A–Q only, including patients outsourced to the private sector • Number of cases per ICD-10 code • Hospital name and postcode Dataset 2: Procedures / Surgery Data For each hospital, please provide: • From 2022 up to the latest data available, preferably by calendar year • Primary procedure OPCS codes, all chapters, including patients outsourced to the private sector • Number of cases per OPCS code • Hospital name and postcode
Date of Response: 13/03/2026
View Response: 11149.pdf
Freedom of Information Request Reference: 11148
Date Received: 09/02/2026
Summary:
Q1. How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to? Q2. How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments: • BR (Bendamustine + rituximab) • VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) • R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) • R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) • CVP (cyclophosphamide, vincristine and prednisolone) • Brukinsa (zanubrutinib) • Imbruvica (ibrutinib) • Velcade (bortezomib) + chemotherapy • Tecartus (brexucabtegene autoleucel) • R-BAC (rituximab, bendamustine and cytarabine) • R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) • Any other systemic anti-cancer therapy • Wait and watch (monitoring only, no active treatment) Q3. How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments: For this question, please only count patients that have received the below treatments for the first time. • BR (Bendamustine + rituximab) • VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone) • R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) • R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine) • CVP (cyclophosphamide, vincristine and prednisolone) • Brukinsa (zanubrutinib) • Imbruvica (ibrutinib) • Velcade (bortezomib) + chemotherapy • Tecartus (CAR-T) • R-BAC (rituximab, bendamustine and cytarabine) • R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone) • Any other systemic anti-cancer therapy • Wait and watch (monitoring only, no active treatment) Q4. If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials.
Date of Response: 17/03/2026
View Response: 11148.pdf
Freedom of Information Request Reference: 11147
Date Received: 09/02/2026
Summary:
How many patients classed as delayed discharge have died annually since 2018-19 to the date you received this request. Please separate each year out into separate figures, for example x in 2018-19, y in 2019-20, z in 2020-21 and so on, and also provide an overall total.
Date of Response: 13/03/2026
View Response: 11147.pdf
Freedom of Information Request Reference: 11146
Date Received: 06/02/2026
Summary:
What NHS Scotland Boards do you take referrals from for PGT-SR IVF? What information or tests need to be completed before a referral is accepted from another board for PGT-SR IVF? What is the current eligibility criteria for PGT-SR IVF? What is the current average waiting time or if this is not available the average waiting time over the past 6 months from date of referral received for IVF with PGT-SR to the first appointment at the fertility centre for this? In recent months on average how long does the process take from an initial appointment at the fertility centre for IVF PGT-SR to the time of when any embryos have been tested with PGT-SR and results have been found for this?
Date of Response: 06/03/2026
View Response: 11146.pdf
Freedom of Information Request Reference: 11145
Date Received: 09/02/2026
Summary:
1. Copies of any internal briefings, papers or correspondence relating to the use of a mutual investment model to deliver a new health centre at East Calder. 2. Copies of any correspondence between the Health Board and the Scottish government regarding the use of a mutual investment model to deliver a new health centre at East Calder. 3. When the health board plans to deliver the new health centre at East Calder as detailed in the Scottish Government's infrastructure delivery plan.
Date of Response: 10/03/2026
View Response: 11145.pdf
Freedom of Information Request Reference: 11144
Date Received: 09/02/2026
Summary:
1. Do any of your wards or seclusion rooms use Oxevision? If yes: 2. Please confirm the number of wards, and provide ward names, where Oxevision is currently used. 3. Please provide your policy or standard operating procedure for the use of Oxevision, up to date at the time of this request. 4. Please provide your Data Protection Impact assessment for the use of Oxevision. 5. Please provide an Equality Impact Assessment in relation to the use of Oxevision. 6. Please state the contract end date(s) for all current contract(s) with Oxehealth/LIO health. 7. Please provide patient posters, leaflets and/or information packs.
Date of Response: 06/03/2026
View Response: 11144.pdf
Freedom of Information Request Reference: 11143
Date Received: 09/02/2026
Summary:
I request is an approximate number of patients on the Cardiac Surgery waiting list? How long is the Cardiac Surgery waiting list at present?
Date of Response: 13/03/2026
View Response: 11143.pdf
Freedom of Information Request Reference: 11142
Date Received: 06/02/2026
Summary:
Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: •ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) •Amivantamab Monotherapy •Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) •Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel •Atezolizumab monotherapy (subcutaneous injection only) •Dabrafenib + Trametinib •Docetaxel monotherapy or in combination with Carboplatin/Cisplatin •Durvalumab •Gemcitabine •Nintedanib + Docetaxel •Nivolumab •Osimertinib •Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) •Paclitaxel •Pembrolizumab Monotherapy •Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) •Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) •Pemetrexed + Platinum (Carboplatin/Cisplatin) •RET Inhibitors (Pralsetinib, Selpercatinib) •Sotorasib •Tepotinib •Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin •Other active systemic anti-cancer therapy •Palliative care only •Amivantamab with carboplatin and pemetrexed •Cemiplimab with platinum-based chemotherapy •Adagrasib •Datopotamab deruxtecan •Amivantamab with lazertinib Q2. Does your trust participate in any clinical trials for Non Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part.
Date of Response: 06/03/2026
View Response: 11142.pdf
Freedom of Information Request Reference: 11141
Date Received: 06/02/2026
Summary:
I am writing to request information regarding NHS Lothian's Occupational Health service and its use of private healthcare providers for staff treatment and assessment. Specifically, I would like to request the total amount of money spent by the NHS Lothian Occupational Health department on referring NHS staff to external private healthcare providers (including but not limited to private hospitals, physiotherapy clinics, and mental health/counselling services). Please exclude costs related to the outsourcing of NHS patient waiting lists; this request is strictly regarding referrals made for NHS staff members via Occupational Health. I would like this financial information broken down by the last five complete financial years (e.g., 2020/21, 2021/22, 2022/23, 2023/24, and 2024/25). For each year, please provide the total cost and, if available within the cost limit, the total number of individual staff referrals associated with this spend.
Date of Response: 05/03/2026
View Response: 11141.pdf
Freedom of Information Request Reference: 11139
Date Received: 05/02/2026
Summary:
In the calendar year 2025, the number of patients in your health board who have been sent to another health board for an outpatient appointment after being referred. Please break this down by the number sent to each different health board, the health board they were sent to, and the type of appointment. In the calendar year 2025, the number of patients in your health board who have been sent to another health board for an outpatient appointment who had still waited over 12 weeks, over six months and over a year for that appointment following being referred.
Date of Response: 03/03/2026
View Response: 11139.pdf
Freedom of Information Request Reference: 11137
Date Received: 05/02/2026
Summary:
1. Who within the Health Board, has the commissioning responsibility for care home placements for older people (aged 65+)? Please provide their: a. Name b. Job title c. Telephone number d. Email address 2. Please provide the gross total expenditure on older person’s (age 65+) services for financial year 2023/24, 2024/25 (actual) and financial year 2025/26 (projected): For question 2a, please provide total spend on personal social services for people aged 65+. This will include spend on residential, nursing, and domiciliary care (2b, 2c, and 2d) as well as other social care for older people such as day services, etc a. Gross total expenditure on older person's (65+) services b. Gross total expenditure on residential home placements (65+) c. Gross total expenditure on nursing home placements (65+) d. Gross total expenditure on domiciliary care/home care (65+) 3. Please provide figures for the total number of older people (aged 65 and over) that the health board has funded during the financial years 2023/24, 2024/25, and 2025/26 (projected). This should include both new placements made during each year and ongoing placements funded by the health board: a. Residential care b. Residential dementia care c. Nursing care d. Nursing dementia care e. Domiciliary care/home care 4. Please provide the total number of adults (aged 18-64) with a primary need of dementia (including early-onset dementia), funded by the Health Board, receiving long-term nursing care in a care home, for the financial year 2023/24, 2024/25 and 2025/26 (projected), broken down by the following weekly fee bands: a. Under £2,000 per week b. Over £2,000 per week 5. Please provide a list of all providers with which the Health Board is funding older people (aged 65+) with dementia receiving nursing care in care homes, where the cost of care exceeds £2,000 per week. 6. Please provide the average (mean) weekly fees paid for care home placements for older people (aged 65+) in financial year 2023/24, 2024/25 and 2025/26: a. Older person’s residential b. Older person’s residential dementia c. Older person’s nursing d. Older person’s nursing dementia 7. Please provide the set or banded weekly fees paid for care home placements for older people (aged 65+) in financial year 2023/24, 2024/25 and 2025/26: a. Older person’s residential b. Older person’s residential dementia c. Older person’s nursing d. Older person’s nursing dementia 8. Please provide the proposed average percentage uplift to the weekly rate paid by the health board between 2024/25 and 2025/26: a. Older person’s residential b. Older person’s residential dementia c. Older person’s nursing d. Older person’s nursing dementia
Date of Response: 03/03/2026
View Response: 11137.pdf
Freedom of Information Request Reference: 11134
Date Received: 04/02/2026
Summary:
Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: •Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) •Abemaciclib + Fulvestrant •Alpelisib + Fulvestrant •Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only •Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel •Atezolizumab •Capivasertib •Capecitabine as a single agent •Carboplatin + Paclitaxel •Elacestrant •Eribulin as a single agent or in combination •Everolimus + Exemestane •Fulvestrant as a single agent •Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) •Palbociclib + Fulvestrant •Parp Inhibitors (Olaparib/Talazoparib) •Pembrolizumab Monotherapy •Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide •Carboplatin + Paclitaxel + Pembrolizumab •Pertuzumab (Perjeta) + Trastuzumab (Herceptin) •Phesgo (Pertuzumab + Trastuzumab in a single injection) •Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) •Ribociclib + Fulvestrant •Sacituzumab Govitecan •Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent •Trastuzumab deruxtecan (Enhertu) •Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel •Trastuzumab emtansine (Kadcyla) •Any other active systemic anti-cancer therapy Q2. In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease): Phesgo (Pertuzumab + Trastuzumab in a single injection) Pertuzumab (Perjeta) + Trastuzumab (Herceptin) Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel Trastuzumab deruxtecan (Enhertu) Trastuzumab emtansine (Kadcyla) Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) Abemaciclib + Fulvestrant Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) Ribociclib + Fulvestrant Capecitabine as a single agent Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Q3. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.
Date of Response: 10/03/2026
View Response: 11134.pdf
Freedom of Information Request Reference: 11133
Date Received: 04/02/2026
Summary:
In early 2022 antivirals were introduced to reduce the impact of Covid-19 on patients. Please can you explain your process for dealing with phone calls from renal transplant patients who were calling to report their Covid illness, including that part of the process where patients were considered for antivirals and levels of immunosuppresants were reviewed/modified for each patient involved. I'd also be grateful if you are able to tell me how many renal patients were involved in this process from 1 January 2022 through to 30 June 2022. I presume calls to renal dept and covid lines would all have been logged with data recoverable. If so, both of those centres. If not, whichever of those two call points was logged with data recoverable.
Date of Response: 05/03/2026
View Response: 11133.pdf
Freedom of Information Request Reference: 11132
Date Received: 04/02/2026
Summary:
Please could you provide a record of: • How many times have your services breached safe staffing levels and across each hospital department since July 2022 - current? • More specifically, when has the Key Decision Maker - Staff Bank Nurse, Executive Director, Clinical Lead, etc - required staffing support from an external resource or third party because there wasn't enough staff on the ward? (Please could you provide: dates, times, ward details, how short were the staff levels were) • What is the minimum requirement of staffing to be available on each ward at any given time?
Date of Response: 13/03/2026
View Response: 11132.pdf
Freedom of Information Request Reference: 11130
Date Received: 03/02/2026
Summary:
1. Mobile MRI and CT contracts Details of the mobile MRI and CT contracts held by your Trust for the periods 2024, 2025 and 2026, including equipment-only rentals as well as fully staffed and managed services. For each contract, please provide: • Contract value(s) • Which modality is the contract for, MRI, CT or Both • Current service provider(s) and the locations at which they operate • Contract duration(s) • Scheduled renewal date(s) • The number of bidders who submitted a response and the names of all bidders • The ranking of all bidders who submitted responses 2. Procurement frameworks Information on the frameworks through which these contracts were procured, including: • Name(s) of the framework(s) utilised • Relevant framework reference number(s) 3. Responsible contacts Contact details for the Radiology Managers and Procurement Managers responsible for overseeing these contracts, including: • Name(s) • Job title(s) • Email address(es) • Telephone number(s)
Date of Response: 16/03/2026
View Response: 11130.pdf
Freedom of Information Request Reference: 11129
Date Received: 03/02/2026
Summary:
1. The budget (monies paid) for forensic medical examiner and advanced forensic nurse practitioner cover to police custody healthcare in each of the last 3 financial years ? 2. The budget (monies paid ) for nursing cover to police custody healthcare for each of the last 3 financial years ?
Date of Response: 04/03/2026
View Response: 11129.pdf
Freedom of Information Request Reference: 11128
Date Received: 03/02/2026
Summary:
I'm getting in touch regarding food and drink served to patients in the health board area. I'm interested to know which food and drink is sourced from overseas and how much has been spent on these foreign foods between January 2021 and December 2025. If you could please offer an annual breakdown of the costs incurred for food and drink that the health board has sourced from abroad and which countries they're from.
Date of Response: 03/03/2026
View Response: 11128.pdf
Freedom of Information Request Reference: 11127
Date Received: 03/02/2026
Summary:
Please provide the following information for your Trust/Board, covering the last five financial years where available (2019/20 - 2024/25). 1. Dermatology Waiting Times and Access Indicators For each financial year listed above, please provide: a.) Referral-to-Treatment (RTT) elective waiting-time indicators for dermatology services, if held: • Median RTT waiting time (in weeks) • Number of patients waiting over 18 weeks (at year-end) • Number of patients waiting over 52 weeks (at year-end) b.) Outpatient dermatology access, if held: • Median waiting time for a first outpatient dermatology appointment (in weeks) • Total number of patients on the dermatology outpatient waiting list at year-end Where possible, please indicate whether data are available broken down by: • New vs follow-up appointments • Sub-specialties within dermatology (e.g. inflammatory skin disease, skin cancer, paediatric dermatology), if routinely recorded 2. Access to Dermatology Care and Capacity (If Held) For each year listed above, please provide: • The total number of consultant dermatologists employed by the Trust/Board (headcount or FTE, whichever is standard) • Whether the Trust/Board commissions or provides specialist dermatology services beyond general dermatology (e.g. severe eczema, psoriasis, acne, or contact dermatitis clinics)
Date of Response: 03/03/2026
View Response: 11127.pdf
Freedom of Information Request Reference: 11126
Date Received: 03/02/2026
Summary:
In the period 1st November 2025 to 31st January 2026 please provide a breakdown of: • Total trust spend with framework agencies for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name In the period 1st November 2025 to 31st January 2026 please provide a breakdown of: • Total trust spend with off-framework agencies for locums doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per agency name In the period 1st November 2025 to 31st January 2026 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum doctors Please provide a further breakdown for locum doctors by: • Spend per grade • Spend per specialty • Spend per internal or associated external provider Please confirm your allocated budget for agency locum doctors for the period 1st November 2025 to 31st January 2026 Please confirm the name of the framework used for the supply of locum doctors in your trust.
Date of Response: 04/03/2026
View Response: 11126.pdf
Freedom of Information Request Reference: 11125
Date Received: 03/02/2026
Summary:
Can I please ask for the following data for 2022-2025, broken down by month: 1. the number of A&E attendances related to ketamine use 2. the number of hospital admissions related to ketamine use
Date of Response: 16/03/2026
View Response: 11125.pdf
Freedom of Information Request Reference: 11124
Date Received: 03/02/2026
Summary:
This request relates to local NHS service pressures associated with obesity and obesity-related illness. We are seeking comparable data across NHS Trusts on both access/waiting times and hospital demand. Please provide the following information for your Trust, covering the last five financial years (2020/21 - 2024/25) 1. Waiting Times and Access Indicators (Local Service Strain) For each year listed above, please provide: a. Referral-to-Treatment (RTT) elective waiting-time indicators, if held: • Median RTT waiting time (in weeks) • Number of patients waiting over 18 weeks (at year-end) • Number of patients waiting over 52 weeks (at year-end) b. The median waiting time for outpatient appointments in the following specialities: • Endocrinology / Diabetes • Cardiology • Orthopaedics 2. Obesity-Related Hospital Admissions and Demand For each year listed above, please provide: a. The total number of inpatient admissions where obesity was recorded as: • A primary diagnosis (ICD-10 code E66), and/or • A secondary diagnosis b. The total number of admissions for the following obesity-related conditions (where obesity is a major risk factor), if available: • Type 2 diabetes (E11) • Coronary heart disease / myocardial infarction (I20–I25) • Stroke (I60–I69) c. If held, the total number of admissions specifically linked to bariatric surgery or specialist weight-management intervention.
Date of Response: 05/03/2026
View Response: 11124.pdf
Freedom of Information Request Reference: 11123
Date Received: 02/02/2026
Summary:
1. A copy of the prevention and management of falls policy/guidance available to staff working within the Adult Psychiatric Unit and St John's Hospital on 19/07/2023. 2. A copy of the management of confused and delirious patients' policy/guidance available to staff working within the Adult Psychiatric Unit and St John's Hospital on 19/07/2023. 3. A copy of the falls prevention risk assessment and care plan used to assess patient risk available to staff working within the Adult Psychiatric Unit and St John's Hospital on 19/07/2023 4. A copy of the level of observation policy/guidance for patient's suffering from confusion/delirium available to staff working within the Adult Psychiatric Unit and in St John's hospital on the 19/07/2023.
Date of Response: 03/03/2026
View Response: 11123.pdf
Freedom of Information Request Reference: 11122
Date Received: 02/02/2026
Summary:
How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Etrasimod • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Mirikizumab • Ozanimod • Risankizumab • Tofacitinib • Upadacitinib • Ustekinumab - Stelara • Ustekinumab Biosimilar • Vedolizumab • Guselkumab
Date of Response: 02/03/2026
View Response: 11122.pdf
Freedom of Information Request Reference: 11119
Date Received: 02/02/2026
Summary:
Can you release: • Number of complaints about maternity services per year over the last 5 years, broken down by: • Issue type (clinical care, communication, attitude/behaviour, consent, postnatal support, mental health, etc.). • Outcome (upheld, partially upheld, not upheld). Number of clinical negligence claims relating to maternity and neonatal care opened and settled each year since 2010, with: • Broad incident category (e.g. intrapartum hypoxia, delayed Caesarean, shoulder dystocia, perineal trauma, stillbirth). • Total and average settlement values by category (you may get banded ranges if they claim cost limits). Any internal guidance, policies or briefing notes on: • Media handling, social media, and engagement with campaign groups relating to maternity services. • How staff are advised to deal with families who are pursuing complaints, FOIs or legal action.
Date of Response: 05/03/2026
View Response: 11119.pdf
Freedom of Information Request Reference: 11116
Date Received: 02/02/2026
Summary:
Can you release copies of current and previous (from 2016) written guidelines on: 1. Growth surveillance in pregnancy (use of uterine artery Dopplers, serial growth scans, thresholds for extra scans). 2. Induction timing for women with hypertension, suspected growth restriction or abnormal Dopplers. Number of obstetric ultrasound scans per year (last 5 years), broken down by: 1. Gestation bands (e.g. 28–31, 32–35, 36–37, 38+ weeks). 2. Indication category: routine pathway vs clinician requested for concern (reduced movements, SFH static/falling, hypertension, etc.). 3. Number and percentage of ultrasound scan requests declined or deferred in maternity services per year, with any internal audits or reviews about reasons (capacity, “not clinically indicated”, etc.). Any internal business cases or evaluation papers for introducing routine late pregnancy scans (e.g. universal 36 week scan) or changing scan frequency, including: 1. Impact on stillbirth/perinatal mortality. 2. Impact on waiting times and ability to provide other clinically indicated scans.
Date of Response: 18/03/2026
View Response: 11116.pdf
Freedom of Information Request Reference: 11113
Date Received: 02/02/2026
Summary:
Please provide copies of all policies, procedures, local guidelines, clinical pathways, protocols, or written instructions held by NHS Lothian that were in force at any time between the 1st of January 2022 and the present, and that relate to maternity care after 37 weeks of pregnancy, specifically: Labour / Intrapartum Care: 1. Management of suspected ruptured membranes after 37 weeks of pregnancy. 2. Monitoring of fetal heart rate after 37 weeks of pregnancy, including documents that specify: o Which types or patterns of fetal heart rate baseline trends are considered clinically concerning or dangerous; and o The criteria, thresholds, or circumstances that require further monitoring, escalation, or intervention. 3. Guidance on performing membrane sweeps at or after 37 weeks, including: o Indications, contraindications, and clinical criteria for offering a sweep; o Recommended technique, frequency, and monitoring before or after the procedure; o Any circumstances under which sweeps should be avoided or escalated; o Written information, advice, or guidance provided to pregnant women regarding sweeps (e.g. leaflets, handouts, consent information, or patient-facing instructions). Infection Management in Pregnancy: 4. Treatment of urinary tract infections in pregnancy, including: o Whether antibiotics may be prescribed prior to receipt of urine culture results; and o Whether antibiotics may be prescribed as a precaution when culture results are pending. Please provide separate documents if different policies apply to first trimester versus full-term pregnancy. 5. Circumstances in which a pregnant woman should be swabbed for Group B Streptococcus carriage.
Date of Response: 03/03/2026
View Response: 11113.pdf
Freedom of Information Request Reference: 11112
Date Received: 30/01/2026
Summary:
Child tooth extractions 1. The number of children (i.e. under 18 years old) who have had a tooth extracted due to tooth decay under general anaesthetic in hospital. Please provide this for the calendar years 2021, 2022, 2023, 2024, and 2025 (most recent data available). 2. The median completed wait for a child tooth extraction due to tooth decay under general anaesthetic in hospital. Please provide this for the calendar years 2021, 2022, 2023, 2024, and 2025 (most recent data available). 3. The longest completed wait for a child tooth extraction due to tooth decay under general anaesthetic in hospital. Please provide this for the calendar years 2021, 2022, 2023, 2024, and 2025 (most recent data available). 4. The number of children currently on a waiting list for a child tooth extraction due to tooth decay under general anaesthetic in hospital. 5. The median ongoing for a child tooth extraction due to tooth decay under general anaesthetic in hospital. 6. The longest ongoing for a child tooth extraction due to tooth decay under general anaesthetic in hospital. Tooth decay 1. The number of children admitted to hospital due to tooth decay. Please provide this for the calendar years 2021, 2022, 2023, 2024, and 2025 (most recent data available).
Date of Response: 27/02/2026
View Response: 11112.pdf
Freedom of Information Request Reference: 11111
Date Received: 30/01/2026
Summary:
1. Does your Trust treat patients for the two following conditions? Yes/No Waldenström macroglobulinaemia (WM) (ICD-10 C88.0) Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4) If yes: 1a. How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions? Waldenström macroglobulinaemia (WM) Marginal zone lymphoma (MZL) 1b. Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials. Waldenström macroglobulinaemia (WM) Marginal zone lymphoma (MZL) Please skip 1c to question 2 and 3. If no: 1c. Which Trust(s) does the Trust refer patients onto for treatment for each of the above conditions? Thank you for answering this survey. 2. How many patients (and new patients* if possible) received treatment for Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025? Waldenström macroglobulinaemia (WM) (ICD-10 C88.0) Fludarabine, cyclophosphamide and rituximab (Known as FCR) Bendamustine in combination with rituximab (Known as BR) Ibrutinib Ibrutinib in combination with rituximab Zanubrutinib Acalabrutinib Chemotherapy (Other than the listed regimens) Wait and watch - no active treatment and monitoring only Any other treatment (Other than the listed regimens) 3. How many patients (and new patients* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025? Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4) Bendamustine in combination with rituximab (Known as BR) Chlorambucil in combination with rituximab (Known as CR) R CVP (Rituximab + cyclophosphamide + vincristine + prednisolone) R CHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone) Zanubrutinib Stem Cell Transplant Wait and watch - no active treatment and monitoring only Any other treatment (Other than the listed regimens) *Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.
Date of Response: 27/02/2026
View Response: 11111.pdf
Freedom of Information Request Reference: 11110
Date Received: 30/01/2026
Summary:
1. How long is your current neurology waiting list? 2. How many women are on the neurology waiting list? Please provide a breakdown of inpatient and outpatients. 3. How many men are on the neurology waiting list? Please provide a breakdown of inpatient and outpatients. 4. How many female patients were diagnosed with a neurology condition in 2025? 5. How many male patients were diagnosed with a neurology condition in 2025? 6. Data on the number of complaints NHS Scotland has received in the last 3 years for late diagnosis (of any condition). 7. Data on the number of complaints NHS Scotland has received in the last 3 years, specifically for late diagnosis of neurological conditions. 8. Data on the number of complaints NHS Scotland has received from women in the last 3 years for late diagnosis (of any condition). 9. Data on the number of complaints NHS Scotland has received in the last 3 years, specifically for late diagnosis of neurological conditions by women.
Date of Response: 18/03/2026
View Response: 11110.pdf
Freedom of Information Request Reference: 11109
Date Received: 30/01/2026
Summary:
I would like to request information about your sterile services department. Specifically: 1. Who conducts instrument sterilisation procedures at your trust? Is it in-house or privately contracted? If privately contracted, please identify the contractor. 2. Please provide compliance scores of any internal and external audits of your sterile services department conducted between 1 January 2022 and the most recent date available, including remedial actions taken. a. Copies of any internal and external audits of sterile services departments between 1 January 2022 until the most recent date available, or the information contained in the reports.
Date of Response: 10/03/2026
View Response: 11109.pdf
Freedom of Information Request Reference: 11108
Date Received: 30/01/2026
Summary:
1) Number of surgical procedures cancelled or postponed since Jan 1st 2022 due to problems with surgical instruments, including: inadequate sterilisation, missing instruments, faulty equipment, or contamination concerns. 2) Number of internal incident reports or safety concerns raised since Jan 1st 2022 from health practitioners referring to issues with surgical equipment or instruments. Please break down the information by calendar year and hospitals in your trust.
Date of Response: 10/03/2026
View Response: 11108.pdf
Freedom of Information Request Reference: 11107
Date Received: 29/01/2026
Summary:
1. The total number of surgical instrument trays processed by your Central Sterile Supply Department (CSSD) since Jan 1st 2022, broken down by calendar year. 2. Total number of surgical instrument trays returned to the Central Sterile Supply Department (CSSD) for being improperly sterilised or unfit for surgery since Jan 1st 2022, broken down by calendar year.
Date of Response: 27/02/2026
View Response: 11107.pdf
Freedom of Information Request Reference: 11106
Date Received: 29/01/2026
Summary:
I would like to know how many CPAP machines NHS Lothian receive per month from April 2024 till now and how many are given out? I would like to know how many of these were to residents in East Lothian in particular. I would also like to know how many people are on the list still waiting and what the longest waiting time for a machine is now.
Date of Response: 26/02/2026
View Response: 11106.pdf
Freedom of Information Request Reference: 11105
Date Received: 29/01/2026
Summary:
I am writing to make a Freedom of Information request to ask for the information your Health Board has recorded in regards to community pharmacy closures. I am looking for information reported and recorded about all closures from Wednesday 01st January 2025 to Wednesday 31st December 2025 inclusive. The precise information I am requesting is, Contractor Code; Name, address, and postcode of pharmacy; Date of closure ; The precise times of closure, and if more than one closure occured in one day, please report each closure as separate; Any reason given for the closure by the contractor, and if none was given recorded please answer n/a or none. I am also looking for both types of closures, those which appear to have been unplanned, and those which were agreed in advance by your health board. If the closure was agreed to and planned in advance can you please state ‘agreed’ or ‘planned’ under ‘reason for closure’, if it was unplanned please give the reason stated by the contractor, if none was given or recorded please state n/a or none.
Date of Response: 26/02/2026
View Response: 11105.pdf
Freedom of Information Request Reference: 11104
Date Received: 29/01/2026
Summary:
1. What is the median completed wait time for patients who require a colposcopy following a routine cervical cancer screening exam, broken down by year from 2019 to 2025? 2. What is the longest completed wait time recorded for a patient who required a colposcopy following a routine cervical cancer screening exam, broken down by year from 2019 to 2025? 3. What is the current median and longest ongoing wait for patients who require a colposcopy following a routine cervical cancer screening exam.
Date of Response: 27/02/2026
View Response: 11104.pdf
Freedom of Information Request Reference: 11103
Date Received: 29/01/2026
Summary:
1. The number of patients under the trust’s care with a recorded diagnosis of Dravet syndrome in each month of 2025 (January–December). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.3 or SNOMED code 230437002. a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ 2. The number of patients under the trust’s care with a recorded diagnosis of Lennox-Gastaut syndrome in each month of 2025 (January-December). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.4 or SNOMED code of 230418006. a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ 3. The number of patients under the trust’s care who have been treated with fenfluramine in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 4. The number of patients under the trust’s care who have been treated with cannabidiol in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 5. The number of patients under the trust’s care who have been treated with cenobamate in in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 6. The number of patients under the trust’s care who have been treated with rufinamide in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 7. The number of patients under the trust’s care who have been treated with stiripentol in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 8. The number of patients under the trust’s care who have been treated with clobazam in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 9. The number of patients under the trust’s care who have been treated with sodium valproate in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 10. The number of patients under the trust’s care who have been treated with topiramate in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 11. The number of patients under the trust’s care who have been treated with lamotrigine in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication.
Date of Response: 26/02/2026
View Response: 11103.pdf
Freedom of Information Request Reference: 11102
Date Received: 29/01/2026
Summary:
1. Which Trusts do you carry out FLT3 testing for? 2. How many FLT3 tests have you done in the last 12 months? 3. How many FLT3 tests have you done in the last 12 months for each of the Trusts in your answer to Question 1? 4. How many positive FLT3 test results have you had in the last 12 months for each of the Trusts in your answer to Question 1?
Date of Response: 26/02/2026
View Response: 11102.pdf
Freedom of Information Request Reference: 11101
Date Received: 29/01/2026
Summary:
Q1. Are there any Specialist Palliative Care Units (SPCUs) within your Trust? If yes, please provide the name and address of these. Q2. Please provide information on the following within your Trust between January 2023 and December 2025 (inclusive). Broken down by year if possible: i) The number of suicides in SPCUs (by adults 18+) ii) The number of attempted suicides in SPCUs (by adults 18+) Q3. Please provide information on the following within your Trust between January 2023 and December 2025 (inclusive), excluding data provided in Q2. Broken down by year if possible: i) The number of suicides in any hospital ward by patients receiving specialist palliative care (by adults aged 18+) ii) The number of attempted suicides in any hospital ward by patients receiving specialist palliative care (by adults aged 18+)
Date of Response: 26/02/2026
View Response: 11101.pdf
Freedom of Information Request Reference: 11100
Date Received: 29/01/2026
Summary:
1. Copies of all risk assessments and policies relating to the disclose of hospital admission records to local authorities/council department. 2. In particular, all risk assessments and policies relating to disclosure of admission and other records from the Royal Infirmary of Edinburgh to East Lothian Council and its Carer departments. 3. Details of processes involved in information sharing of admission records between Royal Infirmary of Edinburgh to East Lothian Council.
Date of Response: 26/02/2026
View Response: 11100.pdf
Freedom of Information Request Reference: 11099
Date Received: 29/01/2026
Summary:
Can I request, broken down by the calendar years 2019, 2020, 2021, 2022, 2023, 2024 and 2025: 1. The total number of referrals for a neurodevelopmental condition assessment. 2. The median completed wait for a neurodevelopmental condition assessment. 3. The median ongoing wait for a neurodevelopmental condition assessment. 4. The longest completed wait for a neurodevelopmental condition assessment. 5. The longest ongoing wait for a neurodevelopmental condition assessment.
Date of Response: 03/03/2026
View Response: 11099.pdf
Freedom of Information Request Reference: 11098
Date Received: 28/01/2026
Summary:
1. How many mammography systems do you have in the trust? 2. Who is the manufacturer of each mammography system within the trust? 3. What is the model of each mammography system within the trust? 4. Trust location of each mammography system within the trust (hospital name/mobile van)? 5. Function of each of the mammography systems (screening/assessment/both)? 6. What was the initial cost of the equipment? 7. What is the annual maintenance cost? 8. What is the acquisition date for each mammography system within the trust? 9. What is the planned replacement date for each mammography system within the trust? 10. How does the Mammography department manage PGMI scoring (e.g. scored by superintendent, shared responsibility on scoring)?
Date of Response: 27/02/2026
View Response: 11098.pdf
Freedom of Information Request Reference: 11097
Date Received: 28/01/2026
Summary:
1) Please state how many full-time (FT) equivalent registered Band 7 and 8 nurses at your health board employs between 2022 and 2026 2) (i) If known, please state how many FT equivalent clinical nurse specialists your health board employs both now and in 2022, please show by AfC band if possible: Number of clinical nurse specialists employed at present time (at band?) Number of clinical nurse specialists employed in 2022 (at band?) (ii) Areas of clinical practice covered 3) Finally, please state how many FT equivalent nurses your health board currently employs:
Date of Response: 27/02/2026
View Response: 11097.pdf
Freedom of Information Request Reference: 11096
Date Received: 28/01/2026
Summary:
Please provide us with the following information: 1. A plan detailing the ward layout/design of ward 70 of the Western General Hospital, Edinburgh. 2. Please highlight the location of room 17 and the nurses’ station that is predominantly used. 3. If there have been any changes in layout since 2023, please include details. 4. Please advise whether there is any policy specific to room allocation. 5. Do you have any policy relating to additional care rounds for patients in single rooms? 6. What additional supervision is in place for patients who lack capacity or have impaired function?
Date of Response: 26/02/2026
View Response: 11096.pdf
Freedom of Information Request Reference: 11095
Date Received: 28/01/2026
Summary:
I write to ask that the Board provides me with the following information: 1. Has the Board obtained their own legal advice on complying with the judgement and with all relevant legislation and regulations, all as set out in Ms Russell’s letter of 30th September 2025 ? 2. If the answer to this is yes, can you please provide me with: a. A copy of the legal advice obtained by the Board b. The total cost to the Board of obtaining that advice c. A copy of any planned actions, including timetables, the Board has drawn up based on the advice received and ensuring that the Board will be compliant, as an employer and as a service provider, with the judgement and with all relevant legislation and regulations d. A note of the total costs anticipated to the Board of changes needed to policy and practice to ensure compliance with the judgement and with all relevant legislation and regulations 3. If the answer is no, can you provide me with a copy of the Board meeting minutes at which the Chief Executive reported receipt of Ms Russell’s letter and an explanation as to why the Board has not sought the legal advice recommended by government ? 4. In either scenario, has the Board flagged the reputational, financial and other risks associated with non-compliance with the judgement and with all relevant legislation and regulations, in the Board’s Corporate Risk Register ? 5. If yes, can you please provide me with a copy of the Corporate Risk Register entry 6. If no, can you please provide me with a copy of papers, emails and any relevant correspondence associated with a decision not to include the matter in the Board’s Corporate Risk Register. 7. Copies of any progress reports on all of the above made to Ms Russell providing the ‘assurances on your work in this area’ as flagged in her letter of 30th September 2025.
Date of Response: 27/02/2026
View Response: 11095.pdf
Freedom of Information Request Reference: 11094
Date Received: 27/01/2026
Summary:
Please provide the number of patient admissions to A&E or Plastic Surgery units in your Board area for complications arising from non-surgical cosmetic procedures (fillers/botulinum toxin) for the financial year 2024-2025. Please specify, where recorded, if the complication arose from a procedure performed by a non-medical practitioner vs a medical practitioner.
Date of Response: 24/02/2026
View Response: 11094.pdf
Freedom of Information Request Reference: 11093
Date Received: 27/01/2026
Summary:
Section 1 Do you compound bespoke parenteral nutrition in your aseptic unit? (This should not include adding vitamins and trace elements to multi chamber licensed products) • Yes • No If no, why? • Completely Outsourced • Patient Numbers • Other, please specify If no, please proceed to Section 2 and 3. If yes, please proceed with the questions below. How do you compound bespoke parenteral nutrition? • Automated Compounding Device (ACDs) • Manual, Gravity or Syringe Fill (Please proceed to Section 2 and 3) • Other, please specify (Please proceed to Section 2 and 3) If you compound bespoke parenteral nutrition with an ACD, please answer the below. How many validated and in-use ACDs do you have in your aseptic unit? How many spares/not in-use ACDs do you have? Do you own your ACDs or are they loaned? How old are your ACDs? • Between 1 and 3 years old • Between 4 and 8 years old • Older than 8 years old Section 2 Do you compound Systemic Anti-cancer Therapies (SACT) (chemotherapy and/or immunotherapy) in your aseptic unit? • Yes • No If no, why? • Completely Outsourced • Patient Numbers • Other, please specify If no, please proceed to Section 3. If yes, please proceed with the questions below. How do you compound chemotherapy? • Manually • Automated compounding devices (ACDs) • Repeater pumps • Other, please specify If you use automation, how many ACDs do you have validated and in use? What drug categories do you compound, and in what quantity? • MABS • Cytotoxics • Other, please specify What are your final filling containers? • IV bags • Syringes • Elastomeric devices • Other, please specify Section 3 Do you compound antibiotic preparations in your aseptic unit? • Yes • No If no, why? • Outsourced • Patient Numbers • Other, please specify If no, please disregard this section. If yes, please proceed with the questions below. How do you compound antibiotics? • Manually • Automated compounding devices (ACDs) • Repeater pumps • Other, please specify If you use automation, how many ACDs do you have validated and in use? What antibiotic quantities do you manufacture? What are your final filling containers? • IV bags • Syringes • Elastomeric devices • Other, please specify
Date of Response: 25/02/2026
View Response: 11093.pdf
Freedom of Information Request Reference: 11092
Date Received: 27/01/2026
Summary:
For each financial year from 2019/20 to 2025/26 (most recent): 1. the total number of referrals for an inguinal hernia repair. 2. the median completed wait for an inguinal hernia repair. 3. the median ongoing wait for an inguinal hernia repair. 4. the longest completed waited for an inguinal hernia repair. 5. the longest ongoing wait for an inguinal hernia repair.
Date of Response: 02/03/2026
View Response: 11092.pdf
Freedom of Information Request Reference: 11091
Date Received: 27/01/2026
Summary:
In light of the Royal College of Nursing's recent report on corridor care in Scotland, can I request the following information for the calendar years a) 2024 and b) 2025: 1. How many incidents have been reported by either a member of staff, patient or family member where care has been delivered in an inappropriate setting? By inappropriate setting, I am using the RCN's definition, as outlined in its report: "By inappropriate setting, we mean a place not designed for patient care, such as a corridor, storage area, waiting room, office or car park. 2. Please provide details for any incident reported in Q1.
Date of Response: 27/02/2026
View Response: 11091.pdf
Freedom of Information Request Reference: 11090
Date Received: 27/01/2026
Summary:
Cataract surgery activity 1. Please confirm the number of cataract procedures performed by the Trust in each of the last three financial years, if available. 2. Intraocular lenses (IOLs) a. Please confirm the current IOL supplier or suppliers used by the Trust for cataract surgery. b. If possible, please indicate the approximate proportion of usage by supplier. c. Are IOLs currently under a formal contract or framework agreement? If yes, please confirm the contract start and end dates. Phacoemulsification equipment 3. How many phacoemulsification machines are currently in clinical use at the Trust? a. Please confirm the manufacturer or supplier of the phaco machines. b. Please provide the year of manufacture or approximate age of each unit. c. Are the phaco machines covered by a service or maintenance contract? If yes, please confirm the contract end date, if available.
Date of Response: 26/02/2026
View Response: 11090.pdf
Freedom of Information Request Reference: 11008
Date Received: 06/01/2026
Summary:
I would like to request the following information for your healthcare trust during the period 1st Jan2015 to 31st December 2025: 1. Annual number of patients diagnosed with blood cancers per year overall, and by subtype: • Lymphomas (C81-86) • Malignant immunoproliferative diseases (C88) • Multiple myeloma and malignant plasma cell neoplasms (C90) • Leukaemia (C91-C95) • Unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues (C96) 2. The number of blood cancer clinical trials available, including active trials that are recruiting and trials that are not actively recruiting. 3. Annual number of patients who were enrolled in interventional or observational clinical trials related to these blood cancers per year. 4. The scientific title, clinical trial registration number, phase (I/II/III/IV/other), opening and closing recruitment dates, number recruited at this trust, and location of each trial related to blood cancer. 5. The current number of dedicated research staff (e.g. research nurses, research practitioners, study coordinators etc.) assigned to haematological clinical trials. 6. If available, annual counts of invitations/offers made to eligible patients to consider trial participation.
Date of Response: 03/02/2026
View Response: 11008.pdf
Freedom of Information Request Reference: 11089
Date Received: 27/01/2026
Summary:
I am interested in the waiting time for people thought to have neurodegenerative conditions such as Alzheimer's or other dementias, What is the longest time someone on such a list has had to wait? How many people are on the list?
Date of Response: 24/02/2026
View Response: 11089.pdf
Freedom of Information Request Reference: 11088
Date Received: 27/01/2026
Summary:
Please can you provide the following for your respective HB: 1. The average ‘injury to spine, decompression surgery interval’ (or be differentiated from general life saving surgery). 2. The number of secondary referrals (%) necessary.
Date of Response: 26/02/2026
View Response: 11088.pdf
Freedom of Information Request Reference: 11087
Date Received: 26/01/2026
Summary:
Q1. How many patients has your Trust treated in the past 12 months (January - December 2025) for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Trust do you refer patients needing treatment to? Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated by the Trust in the past 6 months on the following treatments: •BR (bendamustine + rituximab) •Brukinsa (zanubrutinib) •Calquence (acalabrutinib) •Calquence (acalabrutinib) + Gazyva (obinutuzumab) •Calquence (acalabrutinib) + Venclyxto (venetoclax) •Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab) •FCR (fludarabine + cyclophosphamide + rituximab) •Fludarabine Monotherapy •Gazyva (obinutuzumab) + chlorambucil •Imbruvica (ibrutinib) •Venclyxto (venetoclax) •Venclyxto (venetoclax) + Gazyva (obinutuzumab) •Venclyxto (venetoclax) + rituximab •Zydelig (idelalisib) + rituximab •Imbruvica (Ibrutinib) +Venclyxto (venetoclax) •Any other systemic anti-cancer therapy Q3. How many Chronic Lymphocytic Leukaemia (CLL) patients have received treatment for relapsed/refractory CLL in the past 6 months with the following: •Brukinsa (zanubrutinib) •Calquence (acalabrutinib) •Imbruvica (ibrutinib) •Venclyxto (venetoclax) •Zydelig (idelalisib) + rituximab •Any other systemic anti-cancer therapy Q4. If your Trust does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If yes, please can you provide details of the ongoing trials.
Date of Response: 24/02/2026
View Response: 11087.pdf
Freedom of Information Request Reference: 11086
Date Received: 26/01/2026
Summary:
1) Do you have a shared care framework for GPs in your area about shared care agreements with third party providers for the treatment and management of ADHD? 2) If the answer to 1 above is yes, please provide a copy of your most up to date documents related to shared care agreements with third party providers for the treatment and management of ADHD 3) If the answer to 1 above is no, please provide a copy of any policies or instructions sent to GPs in your area about shared care agreements with third party providers for the treatment and management of ADHD
Date of Response: 24/02/2026
View Response: 11086.pdf
Freedom of Information Request Reference: 11085
Date Received: 26/01/2026
Summary:
As the Board will be aware, the Supreme Court judgement of April last year defined that the protected characteristic of sex in relation to the Equality Act 2020 was biological and binary. This has consequences for NHS Boards in Scotland who have tended to treat ‘gender’ and ‘sex’ as interchangeable, both as an employer and as a service provider. Indeed, on 30th September 2025 Gillian Russell, Director NHS Scotland Health Workforce, wrote to all Boards and advised: Following the Supreme Court Ruling regarding the definition of ‘woman’ in the Equality Act 2010, my colleagues wrote to you on 30 May to bring to your attention to guidance for public bodies https://www.gov.scot/publications/uk-supreme-court-ruling-on-meaning-of-sex-inequality-act-update/. I am now writing to you to reinforce that message, and the importance of Boards ensuring that the law is followed, and the Supreme Court judgement implemented. It is important that Boards, as independent legal entities, seek their own legal advice and are confident that they are complying with the judgement and with all relevant legislation and regulations. I have been unable to find any reference in the Corporate Risk Register to the implications of the Board ensuring it gets legal advice and ensures compliance with the law as an employer as well as a service provider. Given the Employment Tribunal case of 2025 and ongoing and involving NHS Fife and Ms Peggie, this seems remiss. In terms of the Freedom of Information [Scotland] Act 2002, I write to ask for sight of all Board papers, emails and internal correspondence setting how NHS Lothian has responded to Ms Russell’s letter of 30th September 2025, what legal advice the Board has taken, what actions the Board has planned to ensure compliance with the law, and what conclusions were reached on entering the risks around this issue and why it was not entered in the Corporate Risk Register.
Date of Response: 27/02/2026
View Response: 11085.pdf
Freedom of Information Request Reference: 11084
Date Received: 26/01/2026
Summary:
For each calendar year from 2010 to 2024: • Number of recorded cases of postpartum haemorrhage (ICD-10 O72.x) • Number of recorded cases of placenta praevia (ICD-10 O44.x) • Number of recorded cases of placenta accreta spectrum disorders (O43.21–O43.23) • Number of caesarean sections (elective and emergency, if recorded) If available, I would also be grateful for: • Number of peripartum hysterectomies • Number of deliveries requiring blood transfusion
Date of Response: 05/03/2026
View Response: 11084.pdf
Freedom of Information Request Reference: 11083
Date Received: 26/01/2026
Summary:
I do not accept that the application of Sections 38(1)(a)/(b) and 30(b)/(c) justifies a blanket refusal of the information requested. My request concerns governance and complaints-handling processes relating to complaint ~~~~~, not the disclosure of personal medical records. While I acknowledge that Section 38 may apply to certain personal data, this does not exempt NHS Lothian from its duty to consider partial disclosure. The response does not demonstrate that NHS Lothian has appropriately separated disclosable information (e.g. professional roles/job titles, categories of evidence reviewed, timescale management records, and complaint-handling procedures/flowcharts) from any exempt personal information, nor does it explain why anonymised disclosure is not possible. I also dispute the reliance on Section 30(b) and (c). The response does not set out specific and credible prejudice that would be likely to result from disclosure, nor does it evidence the required public interest assessment. In particular, it is unclear how disclosure of high-level governance and process information could prejudice the effective conduct of public affairs, especially where the Board has issued final complaint responses and signposted SPSO escalation. Accordingly, I request that the reviewer reassesses the exemptions applied and confirms what information can be disclosed, including any information that can be provided in anonymised form and any process documentation held.
Date of Response: 24/02/2026
View Response: 11083.pdf
Freedom of Information Request Reference: 11082
Date Received: 26/02/2026
Summary:
1. The eligibility criteria for patients to be referred to the service, and any exclusion criteria that would prevent a referral being accepted. 2. Who is permitted to refer patients to the service (e.g. GP, consultant, allied health professional, self-referral), and how patients or carers contact the service to request an appointment or assessment. 3. The current staffing establishment for the service, including job titles/roles and whole-time equivalent (WTE) for each role. 4. The number of referrals received by the service in each of the last three financial years, including the number of referrals declined in each year. 5. Which clinical systems used (eg EMIS, Vision etc) are used by the service to record patient information.
Date of Response: 24/02/2026
View Response: 11082.pdf
Freedom of Information Request Reference: 11081
Date Received: 26/01/2026
Summary:
I would like to request the following information your organisation may hold regarding incidents of spiking: The number of recorded incidents of suspected spiking cases from October 2021 – September 2025, broken down by month where possible. Where available, provide a breakdown of the information, such as grouped data or percentages: Type of spiking methods – needling, drink spiking, food spiking, vape spiking and any other means Gender – Male, Female, Non-binary, Not disclosed, Other Age group of individuals at the time of alleged spiking – below 18 18 to 24 25 to 34 35 to 44 45 and above Setting/location type where spiking took place (bar, nightclub, private residence, university accommodation, others) Copies of or link to any guidance, protocols, or policies your organisation has for responding to suspected spiking incidents.
Date of Response: 06/03/2026
View Response: 11081.pdf
Freedom of Information Request Reference: 11078
Date Received: 22/01/2026
Summary:
• The total number of diagnostic tests performed for Group A Streptococcus (Strep A) during the calendar years of 2024 and 2025, broken down by test type. • If available, please indicate the type of tests used (e.g., rapid antigen, rapid molecular, culture). • Any associated data on positivity rates for these tests, if recorded.
Date of Response: 26/02/2026
View Response: 11078.pdf
Freedom of Information Request Reference: 11077
Date Received: 21/01/2026
Summary:
1. What is the total annual cost to your health board for all food for patients. (Please can you provide a breakdown for the last five years). 2. What is the top five food products for patients that your health board spends the most money on annually. (Please could you provide that information for the last five years). 3. What food product for patients does your health board spend the least money on annually? (Please provide that information for the last five years). 4. What five most frequent meals provided to patients in your health board.
Date of Response: 26/02/2026
View Response: 11077.pdf
Freedom of Information Request Reference: 11075
Date Received: 21/01/2026
Summary:
I am seeking information about the number of critical incidents declared by all hospitals within your NHS trust during two specific one-year periods: - Period 1: 13th November 2023 - 12th November 2024 - Period 2: 13th November 2024 - 12th November 2025
Date of Response: 17/02/2026
View Response: 11075.pdf
Freedom of Information Request Reference: 11074
Date Received: 21/01/2026
Summary:
I am writing to you under the Freedom of Information (Scotland) Act 2002 to request information relating to the use of off-contract locum staff within NHS Lothian. For the purposes of this request, “off-contract locum spend” should be interpreted as expenditure on temporary clinical staff not sourced via national, regional, or framework agreements. This includes, but is not limited to, non-framework agencies, direct engagements outside approved contracts, or ad-hoc arrangements. Information Requested Please provide the following information for NHS Lothian: 1. Financial Year 2024/2025 The total monetary value (£) of off-contract locum spend incurred between 1 April 2024 and 31 March 2025. 2. Financial Year 2025/2026 (Part Year) The total monetary value (£) of off-contract locum spend incurred between 1 April 2025 and 31 December 2025 (end of Q3). Breakdown (If Available) Where the information is already held in a reportable format, I would be grateful if the totals above could be broken down by: • Clinical staff group (e.g., Medical & Dental, Nursing & Midwifery, AHPs) • Care setting (e.g., Acute, Community, Mental Health) • Directorate, service, or hospital site Please note this breakdown is optional and should only be provided where it does not exceed the cost/time limits set out under FOISA. Additional Context (If Held) If available within existing records, please also confirm: • Whether NHS Lothian operates a formal framework or preferred supplier list for locum staffing. • Whether any internal controls, caps, or approval processes apply specifically to off-contract locum engagements.
Date of Response: 26/02/2026
View Response: 11074.pdf
Freedom of Information Request Reference: 11073
Date Received: 21/01/2026
Summary:
Please can I have a copy of any form of recorded communication (such as emails or reports) between your health board and the Scottish government relating to the creating of a new network of walk-in General Practice services.
Date of Response: 02/03/2026
View Response: 11073.pdf
Freedom of Information Request Reference: 11072
Date Received: 21/01/2026
Summary:
1/ How many referrals have been made to the board's sleep service for suspected sleep apnea in 2024, 2025 and 2026 to date. 2/ What was the average waiting time from referral to treatment for sleep apnea in 2024, 2025 and 2026 to date. 3/ How many deaths have been recorded in the health board region with sleep apnea as either a contributing factor or a comorbidity, in each of the last five years, including 2024 to date.
Date of Response: 02/03/2026
View Response: 11072.pdf
Freedom of Information Request Reference: 11071
Date Received: 21/01/2026
Summary:
Please could I have the following information for 2024/25 and 2025/2026 to day - broken down by year: 1) How many referrals have been made by GPs for assessments for ADHD for a) children b) adults 2) How many referrals have been made by GPs for assessments for autism for a) children b) adults In the case that the board does not specify the condition for each referral, could you provide the general referral numbers for a) children and b) adults across these years. 3) How long is the waiting time in weeks for an ADHD assessment for a) children b) adults 4) How long is the waiting time in weeks for an autism assessment for a) children b) adults In the case that the board does not specify the condition for each referral, could you provide the general referral numbers for a) children and b) adults across these years.
Date of Response: 05/03/2026
View Response: 11071.pdf
Freedom of Information Request Reference: 11070
Date Received: 21/01/2026
Summary:
A) Does your Trust have a process in place for patients who are unable to fit in, or use, an MRI machine but who may need a MRI scan? If so, what is this process? B) Does your Trust send patients who may need an MRI scan who meet the criteria of being unable to use your Trusts’ scanners above, to zoos or vets? C) For the last 3 full calendar years (2023/24/25) and for as much of 2026 as possible please, how many patients have been sent to zoos or vets for MRI scans? D) Does your Trust pay other facilities such as zoos or vets for the use of their MRI machines?
Date of Response: 18/02/2026
View Response: 11070.pdf
Freedom of Information Request Reference: 11069
Date Received: 20/01/2026
Summary:
Please provide the following information: • The total number of Influenza A/B, COVID 19, and RSV diagnostic tests performed by your Trust during the calendar years of 2024 and¬¬¬ 2025, broken down by test type. • If available, please indicate the type of tests used (e.g., rapid antigen, rapid molecular, RT PCR). • Any associated data on positivity rates for these tests, if recorded.
Date of Response: 26/02/2026
View Response: 11069.pdf
Freedom of Information Request Reference: 11068
Date Received: 20/01/2026
Summary:
I am conducting a cost-efficiency review on the use of Ultraviolet light disinfection -UV-C in the trust. I would like to request the following information: • Does the trust use UV-C for surface disinfection • How many UV-C machines has the trust purchased • What were the dates these were purchased • How many were being used in 2025 • What is the total spend on UV-C machines
Date of Response: 23/02/2026
View Response: 11068.pdf
Freedom of Information Request Reference: 11067
Date Received: 20/01/2026
Summary:
car parking permit scoring process 1.) What questions in the 2026/2027 application form relate to each of these application criteria? 2.) The scoring guidelines and points breakdown associated with each section. And how many points are needed for a successful application? 3.) How many people are responsible for scoring each application? Do they work individually? Are applications scored independently and anonymously? If not, what are the reason/s for this? 4.) What specific processes are in place that ensures equity and transparency in the application process?
Date of Response: 26/02/2026
View Response: 11067.pdf
Freedom of Information Request Reference: 11066
Date Received: 19/01/2026
Summary:
Please provide the following information relating to your sexual health service’s provision of intrauterine devices (IUDs/coils): 1. Any current written policies, clinical guidelines, or eligibility criteria governing access to IUD/coil fitting within your service. 2. Whether IUDs/coils are provided by your service for non-contraceptive purposes (including but not limited to management of dysmenorrhoea, menorrhagia, endometriosis or cycle regulation). 3. Whether eligibility for IUD/coil fitting is contingent on pregnancy risk, sexual activity with men, or use for contraception. 4. Any guidance provided to clinicians on assessing patient eligibility where contraception is not required for pregnancy prevention.
Date of Response: 16/02/2026
View Response: 11066.pdf
Freedom of Information Request Reference: 11065
Date Received: 19/01/2026
Summary:
Please provide any information held by East Lothian Health & Social Care Partnership from January 2023 to the present regarding the cessation, suspension, withdrawal, or refusal of shared care arrangements for ADHD medication for patients formally diagnosed by qualified clinicians using DSM 5 criteria or NICE compliant assessment guidelines. Please include: 1. Communications (internal or external) issued by or received by East Lothian HSCP relating to changes in shared care prescribing for ADHD medication. 2. Policies, guidance, protocols, or instructions circulated to GP practices, mental health teams, or pharmacy services regarding shared care prescribing for ADHD. 3. Meeting minutes, reports, briefing papers, or decision making documents that refer to ending, altering, or reviewing shared care arrangements for ADHD medication in East Lothian. 4. Any data held on the number of GP practices in East Lothian that have ceased, paused, or declined shared care requests for ADHD medication since 2023.
Date of Response: 17/02/2026
View Response: 11065.pdf
Freedom of Information Request Reference: 11002
Date Received: 06/01/2026
Summary:
1. The number of patients being removed from an NHS waiting list due to attending or being admitted at the private sector. [Please note: I am referring to patients who have chosen to pay for private treatment; not patients that are being treated as NHS patients at a private healthcare clinic]. I would like this information for the last 8 calendar years (2019, 2020, 2021, 2022, 2023, 2024, 2025 and 2026).
Date of Response: 06/03/2026
View Response: 11002.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Mainpoint
102 Westport
Edinburgh
EH3 9DN

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS